Current Perspectives on HIV-1 Antiretroviral Drug Resistance

被引：126

作者：

Iyidogan, Pinar ^{[1
]}

Anderson, Karen S. ^{[1
]}

机构：

[1] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA

来源：

VIRUSES-BASEL | 2014年 / 6卷 / 10期

基金：

美国国家卫生研究院;

关键词：

HIV-1; antiviral therapy; drug resistance; evolution; lethal mutagenesis; resistance monitoring; IMMUNODEFICIENCY-VIRUS TYPE-1; NONNUCLEOSIDE REVERSE-TRANSCRIPTASE; AMINO-ACID SUBSTITUTIONS; EXPERIENCED HIV-1-INFECTED PATIENTS; DEPENDENT PRIMER UNBLOCKING; SMALL-MOLECULE INHIBITOR; CLEAVAGE SITE MUTATIONS; RNA-POLYMERASE-II; DYNAMICS IN-VIVO; LETHAL MUTAGENESIS;

D O I：

10.3390/v6104095

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Current advancements in antiretroviral therapy (ART) have turned HIV-1 infection into a chronic and manageable disease. However, treatment is only effective until HIV-1 develops resistance against the administered drugs. The most recent antiretroviral drugs have become superior at delaying the evolution of acquired drug resistance. In this review, the viral fitness and its correlation to HIV-1 mutation rates and drug resistance are discussed while emphasizing the concept of lethal mutagenesis as an alternative therapy. The development of resistance to the different classes of approved drugs and the importance of monitoring antiretroviral drug resistance are also summarized briefly.

引用

页码：4095 / 4139

页数：45

共 308 条

[41] Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection [J].

Cooper, David A. ;

Steigbigel, Roy T. ;

Gatell, Jose M. ;

Rockstroh, Jurgen K. ;

Katlama, Christine ;

Yeni, Patrick ;

Lazzarin, Adriano ;

Clotet, Bonaventura ;

Kumar, Princy N. ;

Eron, Joseph E. ;

Schechter, Mauro ;

Markowitz, Martin ;

Loutfy, Mona R. ;

Lennox, Jeffrey L. ;

Zhao, Jing ;

Chen, Joshua ;

Ryan, Desmond M. ;

Rhodes, Rand R. ;

Killar, John A. ;

Gilde, Lucinda R. ;

Strohmaier, Kim M. ;

Meibohm, Anne R. ;

Miller, Michael D. ;

Hazuda, Daria J. ;

Nessly, Michael L. ;

DiNubile, Mark J. ;

Isaacs, Robin D. ;

Teppler, Hedy ;

Nguyen, Bach-Yen .

NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (04) :355-365

[42] The molecular biology of HIV integrase [J].

Craigie, Robert .

FUTURE VIROLOGY, 2012, 7 (07) :679-686

[43] Camelized rabbit-derived VH single-domain Intrabodies Against vif strongly neutralize HIV-1 infectivity [J].

da Silva, FA ;

Santa-Marta, M ;

Freitas-Vieira, A ;

Mascarenhas, P ;

Barahona, I ;

Moniz-Pereira, J ;

Gabuzda, D ;

Goncalves, J .

JOURNAL OF MOLECULAR BIOLOGY, 2004, 340 (03) :525-542

[44] Gag Mutations Strongly Contribute to HIV-1 Resistance to Protease Inhibitors in Highly Drug-Experienced Patients besides Compensating for Fitness Loss [J].

Dam, Elisabeth ;

Quercia, Romina ;

Glass, Baerbel ;

Descamps, Diane ;

Launay, Odile ;

Duval, Xavier ;

Kraeusslich, Hans-Georg ;

Hance, Allan J. ;

Clavel, Francois .

PLOS PATHOGENS, 2009, 5 (03)

[45] 5-Azacytidine Can Induce Lethal Mutagenesis in Human Immunodeficiency Virus Type 1 [J].

Dapp, Michael J. ;

Clouser, Christine L. ;

Patterson, Steven ;

Mansky, Louis M. .

JOURNAL OF VIROLOGY, 2009, 83 (22) :11950-11958

[46] Roles of conformational and positional adaptability in structure-based design of TMC125-R165335 (etravirine) and related non-nucleoside reverse transcriptase inhibitors that are highly potent and effective against wild-type and drug-resistant HIV-1 variants [J].

Das, K ;

Clark, AD ;

Lewi, PJ ;

Heeres, J ;

de Jonge, MR ;

Koymans, LMH ;

Vinkers, HM ;

Daeyaert, F ;

Ludovici, DW ;

Kukla, MJ ;

De Corte, B ;

Kavash, RW ;

Ho, CY ;

Ye, H ;

Lichtenstein, MA ;

Andries, K ;

Pauwels, R ;

de Béthune, MP ;

Boyer, PL ;

Clark, P ;

Hughes, SH ;

Janssen, PAJ ;

Arnold, E .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (10) :2550-2560

[47] High-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: Strategic flexibility explains potency against resistance mutations [J].

Das, Kalyan ;

Bauman, Joseph D. ;

Clark, Arthur D., Jr. ;

Frenkel, Yulia V. ;

Lewi, Paul J. ;

Shatkin, Aaron J. ;

Hughes, Stephen H. ;

Arnold, Eddy .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2008, 105 (05) :1466-1471

[48]

Das K, 2013, CURR OPIN VIROL, V3, P111, DOI 10.1016/j.coviro.2013.03.012

[49] Non-nucleoside reverse transcriptase inhibitors (NNRTIs): Past, present, and future [J].

De Clercq, E .

CHEMISTRY & BIODIVERSITY, 2004, 1 (01) :44-64

[50] Human viral diseases: what is next for antiviral drug discovery? [J].

De Clercq, Erik .

CURRENT OPINION IN VIROLOGY, 2012, 2 (05) :572-579

← 1 2 3 4 5 6 7 8 9 10 →